Added value of [18F]FDG PET/MRI over MDCT alone in the staging of recurrent gastric cancer
Authors:
- 25 March 2021
- journal article
- research article
- Published by Springer Nature in European Radiology
- Vol. 31 (10) , 7834-7844
Abstract
Objectives To investigate whether 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) positron emission tomography/magnetic resonance imaging (PET/MRI) can improve the diagnostic performance of TNM staging and help in making an accurate decision regarding resectability in patients with recurrent gastric cancer compared to multi-detector computed tomography (MDCT). Methods Fifty patients with histologically (n = 31) or clinically (n = 19) confirmed recurrent gastric cancer underwent both MDCT and [18F]FDG PET/MRI. Two radiologists independently assessed TNM staging using MDCT with and without [18F]FDG PET/MRI and scored resectability using a 5-point confidence scale. Diagnostic performance as assessed by radiologists was compared using McNemar’s test and receiver operating characteristic curve analysis. Results Of the 50 patients, pathologic T and N staging was available in seven and six patients, respectively. Diagnostic accuracies for T and N staging were not significantly different between MDCT with and without [18F]FDG PET/MRI for both reviewers (p > 0.05). However, for M staging, diagnostic accuracy was significantly improved when 18F-FDG PET/MRI was added to MDCT alone (68.0% [34/50] to 90.0% [45/50] for reviewer 1 [p = 0.001] and 66.0% [33/50] to 96.0% [46/50] for reviewer 2 [p < 0.001]). Regarding the resectability of recurrent gastric cancers, the addition of [18F]FDG PET/MRI increased the area under the curve values for both reviewers (from 0.860 to 0.989 for reviewer 1 and from 0.778 to 0.898 for reviewer 2), with a statistical significance for reviewer 2 (p = 0.002). Conclusion Compared to MDCT alone, MDCT plus [18F]FDG PET/MRI can improve the diagnostic accuracy for evaluating preoperative M staging as well as resectability for recurrent gastric cancers. Key Points • [ 18 F]FDG PET/MRI can improve diagnostic accuracy for preoperative M staging in patients with recurrent gastric cancers. • [ 18 F]FDG PET/MRI can improve diagnostic accuracy for determining resectability in patients with recurrent gastric cancers. • [ 18 F]FDG PET/MRI can provide critical clues for management options for recurrent gastric cancers.Keywords
Funding Information
- Ministry of Science, ICT and Future Planning (NRF-2019R1F1A1060131)
- Seoul National University Hospital (04-2020-2010)
This publication has 28 references indexed in Scilit:
- Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumoursEuropean Radiology, 2011
- Multivisceral resection for gastric cancer: a systematic reviewGastric Cancer, 2011
- Hybrid PET/MRI of Intracranial Masses: Initial Experiences and Comparison to PET/CTJournal of Nuclear Medicine, 2010
- Value of Retrospective Fusion of PET and MR Images in Detection of Hepatic Metastases: Comparison with 18F-FDG PET/CT and Gd-EOB-DTPA–Enhanced MRIJournal of Nuclear Medicine, 2010
- FDG-PET has no definite role in preoperative imaging in gastric cancerEuropean Journal of Surgical Oncology, 2009
- Clinical Value of Image Fusion from MR and PET in Patients with Head and Neck CancerMolecular Imaging and Biology, 2008
- Imaging Gastric Cancer with PET and the Radiotracers 18F-FLT and 18F-FDG: A Comparative AnalysisJournal of Nuclear Medicine, 2007
- Increased 18F-Fluorodeoxyglucose Uptake in Benign, Nonphysiologic Lesions Found on Whole-Body Positron Emission Tomography/Computed Tomography (PET/CT): Accumulated Data From Four Years of Experience With PET/CTSeminars in Nuclear Medicine, 2007
- Achieving R0 Resection for Locally Advanced Gastric Cancer: is It Worth the Risk of Multiorgan Resection?1Journal of the American College of Surgeons, 2002
- Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal JunctionNew England Journal of Medicine, 2001